Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy; concurrent treatment with agents to prevent skeletal-related events (such as zoledronic acid or denosumab) will be allowed as long as it was initiated prior to study entry
Concurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for prostate cancer.
Patients receiving any other concurrent anticancer or investigational therapy
Concurrent anticancer therapy; however, radiotherapy is allowed
Concurrent therapy: no other concurrent anticancer or investigational therapy permitted except as noted above
No other concurrent anticancer therapy or prior prostate cancer vaccines expressing TARP
Concurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for breast or prostate cancer; patients that have received treatment for a different cancer previously and have been disease-free for less than one year are excluded
Prior or concurrent treatment with any anticancer agent for the same cancer diagnosis
Any concurrent anticancer therapy
Use of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated anti-androgen or bone targeting therapies.
Concurrent treatment with any other anticancer therapy
Concurrent use of conventional or investigational anticancer agents, except hydroxyurea
Concurrent anticancer therapy (including other investigational agents)
Use of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated with LHRH agonist at the time of trial entry
Plans for concurrent anticancer therapy except as permitted
No concurrent anticancer chemotherapy or local therapy
Treatment for malignancy with anticancer therapy, including cytotoxic agents, hormonal agents, or immunotherapy, within  years of enrollment
No other concurrent anticancer therapy
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Concurrent treatment with any other anticancer therapy
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies
Concurrent anticancer treatment or immunosuppressive agents
Concurrent therapy with any other investigational anticancer agent
Patients who are receiving any other investigation agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment and/or radiation therapy is allowed with a  day washout period prior to registration
Concurrent treatment with any anticancer agent outside of this protocol
Other concurrent anticancer therapies.
No other concurrent anticancer therapies or agents
Any concurrent anticancer therapy, excluding hormonal therapy for prostate or breast cancer
Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a  week washout period prior to registration
Concurrent treatment with any other anticancer therapy
Concurrent anticancer therapy (including other investigational agents), with the exception of hormone therapy for prostate cancer
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low-dose corticosteroids for the treatment of non cancer-related illnesses are permitted.
Patients may not be receiving any other experimental agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Use of any other concurrent investigational agents or anticancer agents except for hormonal therapy as outlined in inclusion criteria
Patients must not be receiving other investigational agents or concurrent anticancer therapy
No other concurrent anticancer agents
Other concurrent anticancer chemotherapy
Concurrent anticancer therapy
Concurrent treatment with other anticancer therapy
Receiving concurrent treatment with other anticancer therapy
Concurrent anticancer therapy (including other investigational agents)
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance treatment for prostate cancer